A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Trial Profile

A Phase I/II Study of ODX (Osteodex) in Metastatic Castration Resistant Prostate Cancer (CRPC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Dec 2016

At a glance

  • Drugs Alendronic acid/guanidine dextran conjugate (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Dec 2016 Results published in the Anticancer Research
    • 13 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top